BRAF and neoplasm: To strengthen clinical interpretability, multivariable models were expanded to include treatment line, baseline tumor burden, and molecular markers (BRAF/MSI where available); results were consistent with the primary analysis, supporting the robustness of Δ-GLCM Homogeneity as an independent predictor.